Skip to main content

Novartis confirms unconstrained

Oct 26, 2023 | Press release

Novartis confirms unconstrained PLUVICTO® supply and significantly expands treatment centers

Our guide will help you learn about disease progression for the patients in your care.
Our treatment centre locator

Oct 24, 2023 | Press release

Novartis Financial Results - Q3 2023

Our treatment centre locator will help you find a facility local to your patient, discover what RLI/RLT they offer, and make a referral so they can be treated closer to home.
Novartis PLUVICTO

Oct 23, 2023 | Press release

Novartis PLUVICTO® shows clinically meaningful and highly statistically significant rPFS benefit in patients

Our guide will help you learn about disease progression for the patients in your care.
Our treatment centre

Sep 25, 2023 | Press release

Novartis LUTATHERA® demonstrates clinically meaningful progression-free survival in first line advanced (GEP-NETs)

Our treatment centre locator will help you find a facility local to your patient, discover what RLI/RLT they offer, and make a referral so they can be treated closer to home.
Latest news
  • Press Releases
    Novartis Financial Results - Q3 2023

    Novartis Financial Results - Q3 2023

  • Press Releases
    Novartis confirms unconstrained PLUVICTO® supply and significantly expands treatment centers

    US drug shortage status resolved, as Novartis significantly scales up production of PLUVICTO®.

  • Press Releases
    Novartis PLUVICTO® shows clinically meaningful and highly statistically significant rPFS benefit in patients

    Impressive data and promising PLUVICTO® results at the 2023 European Society for Medical Oncology (ESMO) Congress.

  • Press Releases
    Novartis LUTATHERA® demonstrates clinically meaningful progression-free survival in first line advanced (GEP-NETs)

    LUTATHERA® results represent a significant development in advanced cancer care.